California State Teachers Retirement System Increases Stock Position in Teva Pharmaceutical Industries Ltd (NYSE:TEVA)

California State Teachers Retirement System increased its position in shares of Teva Pharmaceutical Industries Ltd (NYSE:TEVA) by 0.6% during the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 737,152 shares of the company’s stock after buying an additional 4,472 shares during the quarter. California State Teachers Retirement System owned 0.07% of Teva Pharmaceutical Industries worth $11,559,000 at the end of the most recent quarter.

A number of other hedge funds have also recently added to or reduced their stakes in TEVA. FMR LLC raised its holdings in shares of Teva Pharmaceutical Industries by 44.0% in the 4th quarter. FMR LLC now owns 35,248,665 shares of the company’s stock valued at $543,534,000 after purchasing an additional 10,766,729 shares during the period. Brahman Capital Corp. raised its holdings in Teva Pharmaceutical Industries by 67.3% in the 4th quarter. Brahman Capital Corp. now owns 12,248,106 shares of the company’s stock valued at $188,866,000 after acquiring an additional 4,925,245 shares during the period. Polaris Capital Management LLC raised its holdings in Teva Pharmaceutical Industries by 4.4% in the 4th quarter. Polaris Capital Management LLC now owns 10,342,980 shares of the company’s stock valued at $159,489,000 after acquiring an additional 431,942 shares during the period. Norges Bank bought a new position in Teva Pharmaceutical Industries in the 4th quarter valued at about $146,130,000. Finally, Northern Trust Corp raised its holdings in Teva Pharmaceutical Industries by 2.7% in the 4th quarter. Northern Trust Corp now owns 6,687,764 shares of the company’s stock valued at $103,125,000 after acquiring an additional 175,173 shares during the period. 65.08% of the stock is currently owned by institutional investors and hedge funds.

Shares of NYSE TEVA traded up $0.15 during mid-day trading on Friday, reaching $9.23. 17,570,822 shares of the company’s stock traded hands, compared to its average volume of 13,693,786. Teva Pharmaceutical Industries Ltd has a 1-year low of $7.96 and a 1-year high of $25.96. The company has a market capitalization of $9.04 billion, a PE ratio of 3.30, a P/E/G ratio of 1.07 and a beta of 1.64. The business has a 50-day moving average of $9.95. The company has a debt-to-equity ratio of 1.66, a quick ratio of 0.62 and a current ratio of 0.96.

Teva Pharmaceutical Industries (NYSE:TEVA) last released its quarterly earnings results on Thursday, May 2nd. The company reported $0.57 earnings per share for the quarter, topping the consensus estimate of $0.55 by $0.02. The business had revenue of $4.30 billion for the quarter, compared to analysts’ expectations of $4.38 billion. Teva Pharmaceutical Industries had a negative net margin of 18.66% and a positive return on equity of 16.84%. The firm’s revenue for the quarter was down 15.2% compared to the same quarter last year. During the same period in the previous year, the company earned $0.94 earnings per share. As a group, sell-side analysts anticipate that Teva Pharmaceutical Industries Ltd will post 2.27 EPS for the current year.

A number of research analysts have issued reports on TEVA shares. UBS Group started coverage on shares of Teva Pharmaceutical Industries in a research report on Thursday, March 7th. They set a “buy” rating and a $22.00 target price on the stock. CIBC upgraded shares of Teva Pharmaceutical Industries from a “market perform” rating to an “outperform” rating and set a $12.00 target price on the stock in a research report on Monday, June 3rd. SunTrust Banks started coverage on shares of Teva Pharmaceutical Industries in a research report on Tuesday, March 19th. They set a “hold” rating and a $17.00 price target on the stock. Wells Fargo & Co reduced their price target on shares of Teva Pharmaceutical Industries from $20.00 to $18.00 and set a “market perform” rating on the stock in a research report on Wednesday, April 3rd. Finally, BMO Capital Markets started coverage on shares of Teva Pharmaceutical Industries in a research report on Thursday, March 28th. They set a “market perform” rating and a $18.00 price target on the stock. Five research analysts have rated the stock with a sell rating, fifteen have issued a hold rating, four have issued a buy rating and one has assigned a strong buy rating to the company’s stock. The company has an average rating of “Hold” and an average target price of $16.00.

In other news, VP Notaristefani Carlo De sold 16,070 shares of the business’s stock in a transaction that occurred on Monday, May 20th. The shares were sold at an average price of $11.42, for a total value of $183,519.40. Following the sale, the vice president now owns 49,659 shares of the company’s stock, valued at $567,105.78. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, Director Sol J. Barer purchased 111,000 shares of the stock in a transaction dated Monday, June 3rd. The stock was acquired at an average cost of $8.98 per share, for a total transaction of $996,780.00. Following the transaction, the director now owns 115,942 shares of the company’s stock, valued at $1,041,159.16. The disclosure for this purchase can be found here. Insiders own 0.49% of the company’s stock.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic medicines and a portfolio of specialty medicines worldwide. It operates through two segments, Generic Medicines and Specialty Medicines. The Generic Medicines segment offers sterile products, hormones, narcotics, high-potency drugs, and cytotoxic substances in various dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments, and creams.

Recommended Story: Day Trading

Institutional Ownership by Quarter for Teva Pharmaceutical Industries (NYSE:TEVA)

Receive News & Ratings for Teva Pharmaceutical Industries Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries and related companies with MarketBeat.com's FREE daily email newsletter.